CN116942739A - Compound phellodendron bark liquid wet dressing combined silica gel foam dressing for treating pressure sores - Google Patents
Compound phellodendron bark liquid wet dressing combined silica gel foam dressing for treating pressure sores Download PDFInfo
- Publication number
- CN116942739A CN116942739A CN202311103371.8A CN202311103371A CN116942739A CN 116942739 A CN116942739 A CN 116942739A CN 202311103371 A CN202311103371 A CN 202311103371A CN 116942739 A CN116942739 A CN 116942739A
- Authority
- CN
- China
- Prior art keywords
- dressing
- foam dressing
- compound
- silicone foam
- pressure ulcers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004210 Pressure Ulcer Diseases 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 239000007788 liquid Substances 0.000 title claims abstract description 16
- 239000006260 foam Substances 0.000 title claims abstract description 8
- 206010011985 Decubitus ulcer Diseases 0.000 title abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title abstract description 4
- 239000000741 silica gel Substances 0.000 title abstract description 4
- 229910002027 silica gel Inorganic materials 0.000 title abstract description 4
- 241000972673 Phellodendron amurense Species 0.000 title abstract 5
- 229920002323 Silicone foam Polymers 0.000 claims abstract description 21
- 239000013514 silicone foam Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 13
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 5
- 241000258920 Chilopoda Species 0.000 claims abstract description 5
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 5
- 241000245665 Taraxacum Species 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000007799 cork Substances 0.000 claims description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 241000972672 Phellodendron Species 0.000 claims description 4
- 241000576429 Forsythia suspensa Species 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229920003043 Cellulose fiber Polymers 0.000 claims description 2
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000012797 qualification Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 238000001126 phototherapy Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000008738 huangbai Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域Technical field
本发明涉及药物制备技术领域,更具体地说,它涉及一种用于治疗压疮的复方黄柏液湿敷联合硅胶泡沫敷料。The present invention relates to the technical field of pharmaceutical preparation, and more specifically, it relates to a compound cork solution wet compress combined with silicone foam dressing for the treatment of pressure ulcers.
背景技术Background technique
中医认为压疮是指各种致病因素侵袭人体后引起的一切体表化脓感染性疾病的总称,包括急性和慢性两大类。中国古代压疮用以泛指多种外科疾患,后世外科压疮多由毒邪内侵,邪热灼血,以致气血凝滞而成。压疮又称褥疮,是由于身体局部皮肤长期受压,影响血液循环,导致皮肤和皮下组织营养缺乏而出现损伤、溃疡甚至坏死。研究显示,当前老年患者压疮率高达10.4%。压疮常见于重症监护病房长期卧床的老年患者,一旦出现,后续护理治疗不到位,容易造成严重溃烂感染。压疮的治疗方法通常包括定期改变体位、使用特殊的床垫来减轻压力、外用敷料帮助溃疡愈合、保证充足的营养摄入。Traditional Chinese medicine believes that pressure ulcers refer to the general term for all suppurative and infectious diseases on the body surface caused by various pathogenic factors attacking the human body, including acute and chronic categories. In ancient China, pressure ulcers were used to refer to a variety of surgical diseases. In later generations, surgical pressure ulcers were mostly caused by internal invasion of poisonous pathogens, pathogenic heat burning the blood, and stagnation of qi and blood. Pressure ulcers, also known as bedsores, are caused by long-term pressure on local skin of the body, which affects blood circulation, leading to a lack of nutrition in the skin and subcutaneous tissue, resulting in damage, ulcers and even necrosis. Research shows that the current pressure ulcer rate among elderly patients is as high as 10.4%. Pressure ulcers are common in elderly patients who are bedridden in intensive care units for long periods of time. Once they occur, if follow-up care and treatment are not adequate, they can easily lead to severe ulceration and infection. Treatment for pressure ulcers usually includes regular changes in position, using a special mattress to relieve pressure, applying topical dressings to help the ulcer heal, and ensuring adequate nutritional intake.
病房护理老年患者重度压疮(Ⅲ、Ⅳ期)以延长生命、缓解病痛、减少焦虑、服务病人、个体舒适为目的,强化护理服务措施手段的落实,从而全面提升服务质量水平,促进发挥临床护理成效。加强重症监护病房重度压疮老年患者的护理,是营造健康社会环境、倡导健康生活方式的重要手段。The purpose of caring for elderly patients with severe pressure ulcers (stages III and IV) in the ward is to prolong life, relieve pain, reduce anxiety, serve patients, and provide individual comfort, and strengthen the implementation of nursing service measures, thereby comprehensively improving service quality and promoting clinical nursing. Effectiveness. Strengthening the care of elderly patients with severe pressure ulcers in intensive care units is an important means to create a healthy social environment and promote a healthy lifestyle.
现有技术在重度压疮老年患者(Ⅲ、Ⅳ期)护理过程中,采用护理风险管理方法手段,定期护理观察,特别是围绕压疮预防护理措施,开展有针对性的全面观察分析,及时评价压疮预防措施成效,以便于调整下阶段压疮护理的措施。而一般的治疗方式则是采用碘伏皮肤消毒剂局部消毒后辅助光疗照射治疗。在患处以生理盐水冲洗后,取无菌棉球浸透碘伏后均匀涂擦3遍,再以红光治疗仪光照15-20分钟,然后以普通无菌纱布覆盖干预。这种治疗方式的起效时间长,恢复慢,容易引发伤口感染、皮肤溃烂等。The existing technology uses nursing risk management methods and means to carry out regular nursing observations during the nursing process of elderly patients with severe pressure ulcers (stages III and IV), especially around pressure ulcer prevention and nursing measures, to carry out targeted comprehensive observation and analysis and timely evaluation. The effectiveness of pressure ulcer prevention measures can be used to adjust pressure ulcer care measures in the next stage. The general treatment method is to use iodophor skin disinfectant for local disinfection followed by auxiliary phototherapy and irradiation treatment. After flushing the affected area with physiological saline, soak a sterile cotton ball with iodophor and apply it evenly 3 times, then illuminate it with a red light therapy device for 15-20 minutes, and then cover it with ordinary sterile gauze for intervention. This treatment method takes a long time to take effect, slow recovery, and can easily cause wound infection, skin ulceration, etc.
发明内容Contents of the invention
本发明的目的是提供一种用于治疗压疮的复方黄柏液湿敷联合硅胶泡沫敷料,具有较好的临床治疗效果,适合临床推广应用。The purpose of the present invention is to provide a compound cork solution wet compress combined with silicone foam dressing for the treatment of pressure ulcers, which has good clinical therapeutic effect and is suitable for clinical promotion and application.
本发明的上述技术目的是通过以下技术方案得以实现的:一种用于治疗压疮的复方黄柏液湿敷联合硅胶泡沫敷料,包括复方黄柏液湿敷和硅胶泡沫敷料,所述复方黄柏液的主要药用成分包括连翘、黄柏、金银花、蒲公英和蜈蚣;所述硅胶泡沫敷料包括伤口接触层、泡沫层、锁水层和外层薄膜。The above technical objectives of the present invention are achieved through the following technical solutions: a compound cork liquid wet compress combined with a silicone foam dressing for the treatment of pressure ulcers, including a compound cork liquid wet compress and a silicone foam dressing. The main medicinal ingredients include forsythia, cork, honeysuckle, dandelion and centipede; the silicone foam dressing includes a wound contact layer, a foam layer, a water-locking layer and an outer film.
本发明进一步设置为:所述复方黄柏液中各药用成分的重量份数分别为连翘75-85份,黄柏38-43份,金银花38-43份,蒲公英38-43份,蜈蚣2.3-2.5份。The present invention is further configured as follows: the weight parts of each medicinal ingredient in the compound Cortex Phellodendron liquid are respectively 75-85 parts of Forsythia suspensa, 38-43 parts of Cortex Phellodendron, 38-43 parts of Honeysuckle, 38-43 parts of Dandelion, and 2.3-2.3 parts of Centipede. 2.5 servings.
本发明进一步设置为:所述伤口接触层为多孔性软硅胶,所述泡沫层为吸水性聚氨酯,所述锁水层载有吸水颗粒的纤维素纤维基质,所述外层薄膜为可供可溶水蒸气通过的热塑性聚氨酯。The present invention is further configured as follows: the wound contact layer is porous soft silica gel, the foam layer is water-absorbent polyurethane, the water-locking layer is a cellulose fiber matrix carrying water-absorbent particles, and the outer film is available Thermoplastic polyurethane through which dissolved water vapor passes.
本发明还提供一种用于治疗压疮的复方黄柏液湿敷联合硅胶泡沫敷料的使用方法:采用无菌纱布湛取5--10mL复方黄柏液(浸湿纱布)覆盖在创面上,根据创面大小增减无菌纱布,然后在上方覆盖硅胶泡沫敷料。The present invention also provides a method for using compound cork liquid wet compress combined with silicone foam dressing for treating pressure ulcers: use sterile gauze to take 5-10 mL of compound cork liquid (soaked gauze) and cover it on the wound surface. Sterile gauze is added to the size and then covered with a silicone foam dressing over the top.
综上所述,本发明具有以下有益效果:通过复方黄柏液湿敷联合硅胶泡沫敷料治疗老年患者重度压疮(Ⅲ、Ⅳ期),较普通方法有明显优势,有助于提升护理操作的质量、主动性、满意度、及合格率,具有较好的临床治疗效果,适合临床推广应用。In summary, the present invention has the following beneficial effects: treating severe pressure ulcers (stages III and IV) in elderly patients through compound cork solution wet compress combined with silicone foam dressing has obvious advantages over ordinary methods and helps to improve the quality of nursing operations. , initiative, satisfaction, and pass rate, it has good clinical treatment effect and is suitable for clinical promotion and application.
具体实施方式Detailed ways
为使本发明的目的、技术方案和优点更加清楚明白,下面结合实施例,对本发明作进一步的详细说明,本发明的示意性实施方式及其说明仅用于解释本发明,并不作为对本发明的限定。In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below in conjunction with the examples. The schematic embodiments of the present invention and their descriptions are only used to explain the present invention and are not intended to serve as a qualification for the present invention. restrictions.
实施例1:选取90例重度压疮(Ⅲ、Ⅳ期)老年患者(年龄≥65岁)为研究对象,采用不同治疗手段,比较疗效。Example 1: 90 elderly patients (age ≥ 65 years old) with severe pressure ulcers (stages III and IV) were selected as research subjects, and different treatment methods were used to compare the curative effects.
选取2019年1月至2020年12月入住北京中医药大学东直门医院重症监护病房的重度压疮(Ⅲ、Ⅳ期)老年患者(年龄≥65岁)90例作为研究对象。患者平均年龄为75.4±1.78岁,其中男性41名,平均年龄69.4±2.78岁,女性49名,平均年龄78.2±1.78岁。按照随机数字表法分为中药组、敷料组和对照组,每组各30例,分组情况如表1所示。三组患者一般资料比较差异无统计学意义(P>0.05)。研究对象基本情况均已稳定,基础疾病分析:其中恶性肿瘤患者118人,血液疾病患者69人,其他疾病13人。A total of 90 elderly patients (age ≥ 65 years old) with severe pressure ulcers (stages III and IV) admitted to the intensive care unit of Dongzhimen Hospital of Beijing University of Chinese Medicine from January 2019 to December 2020 were selected as the research subjects. The average age of the patients was 75.4±1.78 years old, including 41 males with an average age of 69.4±2.78 years and 49 females with an average age of 78.2±1.78 years. According to the random number table method, they were divided into Chinese medicine group, dressing group and control group, with 30 cases in each group. The grouping situation is shown in Table 1. There was no statistically significant difference in the general information of the three groups of patients (P>0.05). The basic conditions of the research subjects are all stable. Analysis of basic diseases: 118 patients with malignant tumors, 69 patients with blood diseases, and 13 patients with other diseases.
纳入标准:①患者年龄≥65岁;②根据美国国家压疮咨询委员会(NPUAP)对压疮的定义和分期标准,符合重度压疮(Ⅲ、Ⅳ期)诊断,且已接受对症支持治疗;③未出现危及生命情况;④患者及家属了解临床治疗方案,自愿参与本次临床研究。排除标准:①患者符合重度压疮(Ⅲ、Ⅳ期)诊断,尚在接受积极支持治疗;②合并精神心理疾病。Inclusion criteria: ① Patients are ≥65 years old; ② According to the definition and staging standards of pressure ulcers by the National Pressure Ulcer Advisory Panel (NPUAP), they meet the diagnosis of severe pressure ulcers (stages III and IV) and have received symptomatic and supportive treatment; ③ No life-threatening conditions occurred; ④ The patients and their families understood the clinical treatment plan and voluntarily participated in this clinical study. Exclusion criteria: ① Patients meet the diagnosis of severe pressure ulcers (stages III and IV) and are still receiving active supportive treatment; ② Combined with mental illness.
表1不同组别研究对象性别组成和平均年龄对比Table 1 Comparison of gender composition and average age of research subjects in different groups
三组患者首先评估伤口情况,伤口若有异味,进行细菌培养后再行治疗。治疗过程中应充分考虑患者意愿,若患者存在疑问需及时予以解答。The patients in the three groups first evaluated the wound condition. If the wound smelled bad, bacterial culture was performed before treatment. The patient's wishes should be fully considered during the treatment process, and any questions the patient has should be answered promptly.
中药组采用复方黄柏液湿敷联合硅胶泡沫敷料治疗。患处以生理盐水冲洗后,取无菌纱布叠放3-5层,用复方黄柏液浸透后直接敷于患处,10-15分钟后替换纱布继续湿敷,重复3-5次,总用时约为45~90分钟。湿敷过程中,若患者有刺激痛感则适当稀释药液;若伤口有液体渗出,则用盐水棉球擦拭后,再用复方黄柏液浸透纱布湿敷。湿敷结束后患处以硅胶泡沫敷料覆盖干预。The traditional Chinese medicine group was treated with compound Huangbai liquid wet compress combined with silicone foam dressing. After flushing the affected area with physiological saline, stack 3-5 layers of sterile gauze, soak it with compound cork solution and apply it directly to the affected area. After 10-15 minutes, replace the gauze and continue wet compressing. Repeat 3-5 times. The total time is about 45 to 90 minutes. During the wet compress process, if the patient feels irritation and pain, dilute the solution appropriately; if there is fluid leakage from the wound, wipe it with a saline cotton ball and then apply it with gauze soaked in compound cork solution. After the wet compress is completed, the affected area is covered with silicone foam dressing for intervention.
敷料组采用碘伏皮肤消毒剂局部消毒后硅胶泡沫敷料覆盖治疗。患处以生理盐水冲洗后,取无菌棉球浸透碘伏后均匀涂擦3遍,再以硅胶泡沫敷料覆盖干预。The dressing group was treated with local disinfection using iodophor skin disinfectant and then covering with silicone foam dressing. After flushing the affected area with normal saline, soak a sterile cotton ball with povidone iodine and apply it evenly 3 times, and then cover it with silicone foam dressing for intervention.
对照组采用碘伏皮肤消毒剂局部消毒后辅助光疗照射治疗。患处以生理盐水冲洗后,取无菌棉球浸透碘伏后均匀涂擦3遍,再以红光治疗仪光照15-20分钟,然后以普通无菌纱布覆盖干预。The control group was treated with local disinfection with iodophor skin disinfectant followed by auxiliary phototherapy and irradiation. After flushing the affected area with physiological saline, soak a sterile cotton ball with iodophor and apply it evenly 3 times, then illuminate it with a red light therapy device for 15-20 minutes, and then cover it with ordinary sterile gauze for intervention.
三组患者均干预14天,每日测量压疮长度、深度和面积,并分别于第7天、第14天重新评估压疮分期。Patients in the three groups were intervened for 14 days, and the length, depth, and area of pressure ulcers were measured daily, and the pressure ulcer staging was re-evaluated on the 7th and 14th days respectively.
实施例2:观察指标Example 2: Observation indicators
(1)压疮的长度、深度、面积:1个疗程(为期14天)后,计算三组患者压疮长度、深度、面积的变化。如果压疮的长度、深度、面积缩小10%—40%则为基本愈合;如果压疮的长度、深度、面积缩小40%—60%则为显著愈合;如果压疮的长度、深度、面积缩小60%以上,且无渗出液情况,则表示治疗显著有效。(1) Length, depth, and area of pressure ulcers: After one course of treatment (14 days), the changes in length, depth, and area of pressure ulcers in the three groups of patients were calculated. If the length, depth, and area of the pressure ulcer are reduced by 10% to 40%, it is basically healed; if the length, depth, and area of the pressure ulcer are reduced by 40% to 60%, it is significantly healed; if the length, depth, and area of the pressure ulcer are reduced by If it is above 60% and there is no exudate, it means that the treatment is significantly effective.
(2)护理满意度:采用本院自制的护理满意度问卷进行评估。问卷包括患者对压疮护理的态度、满意度及接受度等(分为很满意、满意以及不满意),护理结束后评估。满分为100分,分为非常满意(90分以上)、比较满意(70分至90分)、不满意(70分以下)。(2) Nursing satisfaction: evaluated using the nursing satisfaction questionnaire developed by our hospital. The questionnaire includes the patient's attitude, satisfaction and acceptance of pressure ulcer care (divided into very satisfied, satisfied and dissatisfied), and is evaluated after the care. The full score is 100 points, divided into very satisfied (above 90 points), relatively satisfied (70 to 90 points), and dissatisfied (below 70 points).
(3)压疮周边炎症发生率、伤口愈合率:1个疗程后,观察三组患者较治疗前的压疮周边炎症发生率和伤口愈合率。(3) Incidence of inflammation around pressure ulcers and wound healing rate: After one course of treatment, the incidence of inflammation around pressure ulcers and wound healing rate of the three groups of patients were observed compared with those before treatment.
(4)治疗恢复率和治疗完全恢复率:1个疗程后,观察三组患者较治疗前的治疗恢复率和完全治疗恢复率。(4) Treatment recovery rate and complete treatment recovery rate: After 1 course of treatment, observe the treatment recovery rate and complete treatment recovery rate of the three groups of patients compared with before treatment.
(5)护理相关不良事件发生率:观察三组患者在治疗3天、7天和14天后的护理相关不良事件发生率,包括护理操作事故、患者不适、患者投诉等情况,并记入观察记录。(5) Incidence rate of nursing-related adverse events: Observe the incidence rate of nursing-related adverse events in the three groups of patients after 3 days, 7 days and 14 days of treatment, including nursing operation accidents, patient discomfort, patient complaints, etc., and record them in the observation record .
实施例3:结果Example 3: Results
如表2所示,三组患者压疮愈合情况对比治疗前、治疗后有明显差别。治疗前症状差异无统计学意义(P>0.05),经过系统治疗以后,中药组的压疮长度、深度、面积缩小值(69%、59%、61%)和敷料组的压疮长度、深度、面积缩小值(65%、55%、59%)明显优于对照组长度、深度、面积缩小值(33%、40%、39%),三组比较差异均有统计学意义(P<0.05)。压疮长度、深度、面积显著缩小的平均起效时间,中药组(5.7天)、辅料组(6.5天),也明显优于对照组(13.2天)(P<0.05)。As shown in Table 2, the pressure ulcer healing conditions of the three groups of patients were significantly different before and after treatment. There was no statistically significant difference in symptoms before treatment (P>0.05). After systemic treatment, the length, depth, and area of pressure ulcers in the traditional Chinese medicine group decreased by 69%, 59%, and 61%, and the pressure ulcer length and depth in the dressing group , area reduction values (65%, 55%, 59%) were significantly better than the length, depth, and area reduction values of the control group (33%, 40%, 39%), and the differences between the three groups were statistically significant (P<0.05 ). The average onset time of significant reduction in the length, depth, and area of pressure ulcers was also significantly better in the traditional Chinese medicine group (5.7 days) and the excipient group (6.5 days) than in the control group (13.2 days) (P<0.05).
表2不同组别压疮的长度、深度、面积缩小度对比Table 2 Comparison of length, depth, and area reduction of pressure ulcers in different groups
本研究结果显示三组患者压疮愈合情况对比治疗前、治疗后有明显差别,中药组、敷料组在压疮伤口愈合的起效时间上明显优于对照组,说明复方黄柏液湿敷联合硅胶泡沫敷料治疗可以明显缩短起效时间、提升伤口愈合程度。The results of this study show that there is a significant difference in the healing of pressure ulcers between the three groups of patients before and after treatment. The onset time of pressure ulcer wound healing in the traditional Chinese medicine group and the dressing group is significantly better than that in the control group, indicating that compound Huangbai liquid wet compress combined with silicone Foam dressing treatment can significantly shorten the onset of effect and improve wound healing.
如表3所示,三组患者治疗前症状差异无统计学意义(P>0.05),经过系统治疗以后,三组患者压疮周边炎症发生率、伤口愈合率对比治疗前、治疗后有明显差别。中药组的压疮周边炎症发生率、伤口愈合率(19%、69%)和敷料组的周边炎症发生率、伤口愈合率(25%、55%),明显优于对照组(33%、40%),三组比较差异均有统计学意义(P<0.05)。As shown in Table 3, there was no statistically significant difference in symptoms between the three groups of patients before treatment (P>0.05). After systemic treatment, the incidence of inflammation around pressure ulcers and the wound healing rate of the three groups of patients were significantly different before and after treatment. . The incidence rate of peripheral inflammation and wound healing rate of pressure ulcers in the traditional Chinese medicine group (19%, 69%) and the dressing group (25%, 55%) were significantly better than those in the control group (33%, 40%). %), the differences among the three groups were statistically significant (P<0.05).
表3不同组别压疮周边炎症发生率和伤口愈合率对比Table 3 Comparison of the incidence of inflammation and wound healing rate around pressure ulcers in different groups
如表4所示,中药组、敷料组护理满意度明显高于对照组,差异有统计学意义(P<0.05)。As shown in Table 4, the nursing satisfaction of the traditional Chinese medicine group and dressing group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05).
表4不同组别患者护理满意度对比Table 4 Comparison of nursing satisfaction among different groups of patients
如表5所示,中药组护理相关不良事件发生率(7.9%)、敷料组护理相关不良事件发生率(6.5%)低于对照组(15.9%),三组间的差异具有统计学意义(P<0.05)。As shown in Table 5, the incidence rate of nursing-related adverse events in the traditional Chinese medicine group (7.9%) and the incidence rate of nursing-related adverse events in the dressing group (6.5%) were lower than those in the control group (15.9%), and the differences between the three groups were statistically significant ( P<0.05).
表5不同组别病房护理相关不良事件发生率Table 5 Incidence rates of nursing-related adverse events in different groups of wards
本具体实施例仅仅是对本发明的解释,其并不是对本发明的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本发明的权利要求范围内都受到专利法的保护。This specific embodiment is only an explanation of the present invention, and it is not a limitation of the present invention. Those skilled in the art can make modifications to this embodiment without creative contribution as needed after reading this specification. However, as long as the rights of the present invention are All requirements are protected by patent law.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311103371.8A CN116942739A (en) | 2023-08-30 | 2023-08-30 | Compound phellodendron bark liquid wet dressing combined silica gel foam dressing for treating pressure sores |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311103371.8A CN116942739A (en) | 2023-08-30 | 2023-08-30 | Compound phellodendron bark liquid wet dressing combined silica gel foam dressing for treating pressure sores |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116942739A true CN116942739A (en) | 2023-10-27 |
Family
ID=88449397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311103371.8A Pending CN116942739A (en) | 2023-08-30 | 2023-08-30 | Compound phellodendron bark liquid wet dressing combined silica gel foam dressing for treating pressure sores |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116942739A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171298A1 (en) * | 2009-08-20 | 2012-07-05 | Rongxiang Xu | Use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer |
CN106031756A (en) * | 2015-03-12 | 2016-10-19 | 山东汉方制药有限公司 | Compound amur cork-tree temperature-sensitive gel for treating sore and ulcer and traumatic infection and preparing method thereof |
CN106581532A (en) * | 2017-02-22 | 2017-04-26 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine wet compress preparation for treating hemorrhoid and anal fistula postoperative edema and preparation method thereof |
CN107753521A (en) * | 2016-08-23 | 2018-03-06 | 山东汉方制药有限公司 | The application of a kind of Scolopendra extract and active component in wound repair field |
CN213697192U (en) * | 2020-09-30 | 2021-07-16 | 北京中医药大学东直门医院 | Disposable oral cavity aseptic towel |
CN216652633U (en) * | 2021-10-29 | 2022-06-03 | 振德医疗用品股份有限公司 | Silica gel foam dressing |
-
2023
- 2023-08-30 CN CN202311103371.8A patent/CN116942739A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171298A1 (en) * | 2009-08-20 | 2012-07-05 | Rongxiang Xu | Use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer |
CN106031756A (en) * | 2015-03-12 | 2016-10-19 | 山东汉方制药有限公司 | Compound amur cork-tree temperature-sensitive gel for treating sore and ulcer and traumatic infection and preparing method thereof |
CN107753521A (en) * | 2016-08-23 | 2018-03-06 | 山东汉方制药有限公司 | The application of a kind of Scolopendra extract and active component in wound repair field |
CN106581532A (en) * | 2017-02-22 | 2017-04-26 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine wet compress preparation for treating hemorrhoid and anal fistula postoperative edema and preparation method thereof |
CN213697192U (en) * | 2020-09-30 | 2021-07-16 | 北京中医药大学东直门医院 | Disposable oral cavity aseptic towel |
CN216652633U (en) * | 2021-10-29 | 2022-06-03 | 振德医疗用品股份有限公司 | Silica gel foam dressing |
Non-Patent Citations (3)
Title |
---|
"硅胶泡沫敷料", Retrieved from the Internet <URL:https://db.yaozh.com/jinkoujixie/7393816640000023.html> * |
林莎莎;等: "复方黄柏液湿敷治疗Ⅱ、Ⅲ期压疮的临床疗效观察", 临床合理用药, vol. 07, no. 08, 31 August 2014 (2014-08-31), pages 3 * |
赵丹;: "复方黄柏液辅以红光仪治疗老年重度压疮的疗效观察", 实用药物与临床, vol. 18, no. 06, 15 June 2015 (2015-06-15), pages 740 - 742 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bale et al. | A comparison of two amorphous hydrogels in the debridement of pressure sores | |
CN101991688A (en) | Application of medicinal composition to the preparation of medicament for treating diabetic ulcers | |
Abdoli et al. | The effect of topical olive oil dressing on the healing of grade 1 and 2 diabetic foot ulcers: An assessor-blind randomized controlled trial in type 2 diabetes patients | |
Xu et al. | [Retracted] Clinical Study on the Efficacy of Silver Ion Dressing Combined with Prontosan Gel Dressing in the Treatment of Diabetic Foot Ulcers and the Effect on Serum Inflammatory Factors | |
CN102579650A (en) | Medicinal composition for preventing or/and treating pressure sore, as well as preparation method and application thereof | |
Orlando | Pressure ulcer management in the geriatric patient | |
CN101433617B (en) | Disinfecting paste for dissolving wart and eliminating wart | |
CN116942739A (en) | Compound phellodendron bark liquid wet dressing combined silica gel foam dressing for treating pressure sores | |
CN100434083C (en) | Medicinal use of fugu cod liver oil | |
CN114470056B (en) | A Chinese medicinal preparation for treating lower limb venous ulcer, and its preparation method and application method | |
Ji et al. | Sanguis draconis (Daemonorops draco): a case report of treating a chronic pressure ulcer with tunneling | |
Guo et al. | Effect of combining immersion therapy with Shengji Ointment on wound healing rate and adverse reaction rate in patients with second‐degree burn | |
CN103816326A (en) | A kind of traditional Chinese medicine oil for treating refractory pressure sore | |
CN102697925A (en) | Traditional Chinese medicine combination for treating aural eczema | |
CN108635362B (en) | Pharmaceutical composition for treating diabetic foot | |
Zanaty et al. | The Effect of Aloe Vera on the Healing of Second-Degree Pressure Ulcers among Critically Ill Patients | |
CN104306707A (en) | Medicament composition for treating bedsore | |
CN104524002A (en) | Inflammation-diminishing and skin-reproducing oil gauze for treating diabetic feet and preparation method of oil gauze | |
Farzami et al. | The Effect of Aloe Vera and Honey Dressings on Preventing Pressure Injuries in High-Risk Elderly ICU Patients: A Randomized Clinical Trial. | |
CN1256089C (en) | Medicine kuchuangsan for curing bed sore | |
CN104306442A (en) | Folium ilicis chinensis spray for treating traumatic ulcer | |
CN105106475A (en) | Traditional Chinese medicine gel used for treating toxin-accumulating rotting and ulcerating type bedsores during clinical nursing | |
CN1137917A (en) | Compound jiabing ear drops and preparation method thereof | |
CN119656243A (en) | A Chinese medicine composition for treating bedsores and its oil gauze product and application | |
CN107007683A (en) | Chinese medicine composition and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20231027 |
|
RJ01 | Rejection of invention patent application after publication |